Hi there, Thank you for subscribing to MarketBeat Daily Ratings. We're excited to have you onboard! Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. Please take a moment to confirm your subscription by clicking the link below. You may not receive your daily ratings newsletter without confirming your subscription. Click Here to Confirm Your Subscription to MarketBeat Daily Ratings Thank you again for subscribing. We look forward to being an important part of your investing journey.
Matthew Paulson
Founder and CEO, MarketBeat.
Confirm Your Subscription to MarketBeat Daily Ratings Here
For Your Education and Enjoyment 3 Under-the-Radar Biotechs Under $5 That Could Soar 200%Written by Chris Markoch. Published 9/9/2025. 
Key Points - Hoth Therapeutics is advancing mRNA-based therapies for cancer and obesity, with analyst targets implying over 150% upside.
- Silo Pharma combines pre-clinical psychedelic therapies with an obesity drug collaboration and a unique crypto treasury strategy.
- Anixa Biosciences develops cancer immunotherapies in partnership with leading institutions, with nearly 200% analyst upside potential.
Investing in biotechnology stocks is often considered speculative. Many of these companies are still in clinical or preclinical stages, meaning they aren't yet profitable—and some haven't even generated revenue. As a result, any meaningful payoff could be several years away. On the flip side, a number of biotech names trade below $5 per share, placing them in the "penny stock" category. That low price point can attract traders looking for technical setups and quick gains. Gold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real opportunity isn't in coins or bullion. In every major gold rally of the past 50 years, there's been another investment that has delivered dramatically higher returns. See the full strategy behind this rare opportunity For investors with a longer time horizon and a higher risk tolerance, small-cap biotech stocks offer the chance to build positions that could deliver outsized returns down the road. Below are three under-the-radar biotech firms—each trading under $5 per share—that patient investors might want to consider. Hoth: Pre-Clinical Cancer Research with Big Market Potential Hoth Therapeutics Inc. (NASDAQ: HOTH) leads this list, with shares up 98% year-to-date. Even so, at roughly $1.50 per share, the stock sits about 35% below its 12-month high from January. Hoth is still in the pre-revenue stage, but it has a diversified pipeline of six pre-clinical assets targeting two high-demand markets: oncology and weight-loss treatments. The spotlight is on its HT-KIT candidate, which uses mRNA technology to treat gastrointestinal stromal tumors (GIST), systemic mastocytosis and certain leukemias. In vitro data show HT-KIT achieves over 80% knockdown of KIT expression—the oncogenic driver in several aggressive cancers. Beyond oncology, Hoth's HT-VA obesity drug, licensed exclusively from the U.S. Department of Veterans Affairs, could tap into a multibillion-dollar weight-loss market. Analysts assign Hoth a consensus price target of $4, implying roughly 150% upside from current levels. Silo Pharma: Psychedelics, Obesity Treatment and a Crypto Twist Silo Pharma Inc. (NASDAQ: SILO) offers exposure to novel therapeutics and emerging markets. While shares are down 29% in 2025, they've climbed more than 7% over the past three months after the company signed a non-binding letter of intent to form a 50/50 joint venture with Hoth Therapeutics. If finalized, that deal would grant Silo a stake in HT-VA, Hoth's obesity candidate—an addressable market projected to exceed $100 billion globally. Silo's core focus remains "novel formulations of traditional and psychedelic therapeutics." The company has four pre-clinical candidates, including SP-26 for fibromyalgia and SPU-16 for multiple sclerosis. Adding another speculative angle, Silo recently launched a cryptocurrency treasury strategy. The plan calls for investments in Bitcoin, Ethereum and Solana, with staking used to generate yield while preserving capital. Anixa: Micro-Cap Cancer Play with Major Partnerships Anixa Biosciences (NASDAQ: ANIX) is a micro-cap oncology specialist that's a step further along the development curve. Two of its five pipeline candidates are in Phase 1 clinical trials: - A CAR-T immunotherapy designed to activate a patient's T cells against ovarian cancer.
- A vaccine approach that generates tumor-specific antigens.
Each program is being advanced in partnership with leading institutions—including the Moffitt Cancer Center, the Cleveland Clinic and the U.S. Department of Defense. Although Anixa receives limited analyst coverage, the three reported forecasts average out to a $10 price target, suggesting nearly 200% upside from current levels.
| 
